Standard BioTools Inc. Stock Analysis & AI Score
Standard BioTools Inc. (LAB) has an ST Score of 60.5 (B), driven by its Forecast (A) and held back by its Profitability (C-). Analysts rate it Buy with a $3.25 price target (+337.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Medical - Specialties |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Standard BioTools Inc. (LAB) has an ST Score of 60.5 (B), driven by its Forecast (A) and held back by its Profitability (C-). Analysts rate it Buy with a $3.25 price target (+337.4% upside).
- Strongest
- ForecastA
- Weakest
- ProfitabilityC-
All factor grades
- ForecastA
- ValuationA-
- Financial StrengthB+
- GrowthB
- MomentumC+
- ProfitabilityC-
- Piotroski3/9
Contact
LAB stock: frequently asked questions
What is LAB's ST Score?
Standard BioTools Inc. (LAB) has an ST Score of 60.5 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is LAB a buy, hold, or sell?
Analysts rate LAB a Buy, with a price target of $3.25 (+337.4% vs the current price). Our ST Score grades it B (60.5/100). The ST Score is a data-driven signal, not a recommendation.
What are LAB's factor grades?
Valuation A-, Profitability C-, Financial Strength B+, Momentum C+, Growth B, Forecast A.
What is LAB's valuation grade?
Standard BioTools Inc. (LAB) earns a valuation grade of A-, measured against Medical - Specialties peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is LAB's growth grade?
Standard BioTools Inc. (LAB) earns a growth grade of B, measured against Medical - Specialties peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is LAB's profitability grade?
Standard BioTools Inc. (LAB) earns a profitability grade of C-, measured against Medical - Specialties peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is LAB's financial strength grade?
Standard BioTools Inc. (LAB) earns a financial strength grade of B+, measured against Medical - Specialties peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for LAB?
The average analyst price target for Standard BioTools Inc. (LAB) is $3.25 from 10 analysts, which is +337.4% versus the recent price of $0.74.
What is LAB's Piotroski score?
Standard BioTools Inc. (LAB) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.